Resibufogenin has been found to inhibit the growth and metastasis of CRC by upregulating RIPK3 expression and enhancing the phosphorylation of serine residue 358 of mixed lineage kinase domain‐like protein (MLKL), thereby activating O‐GlcNAcylation of liver glycogen phosphorylase (PYGL), glutamate delta receptors 1 (GLUD1), and glutamate‐ammonia ligase (GLUL) expression in a RIPK3‐dependent manner. Here, RIPK3 is linked to colorectal carcinoma.